How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Matt Blackman has 25+ years of experience as a financial writer and 11+ years of expertise as a research analyst; contributes to several publications. Fibonacci levels are horizontal lines on a ...

Recent insider activity at Recursion Pharmaceuticals included 2 transactions totaling $97,222.74. One was a tax payment of $18,400.36 and the other was a sale of $78,822.38. Average transaction ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.